Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA updates clinical trial eligibility guidance

9 September 2026 · By · Wire by Fusion42

Published

9 September 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at beckersoncology.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

The FDA's Oncology Center of Excellence updated clinical trial eligibility guidance to expand inclusion criteria and improve safety monitoring through real-time trial review in partnership with major cancer centers and pharma companies.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You need to revisit your trial protocols now that the FDA is widening patient eligibility and reviewing safety during trials. This opens access to more participants but tightens real-time safety scrutiny on your study design.

◆ Coverage

1 source · 9 Sep 2026

◆ Related on Wire

◆ Topics

Healthfdaclinical-trialsoncologyregulatory-updatestrial-eligibility